Cyclacel terminates CMO Mark Kirschbaum; appoints board member Brian Schwartz as interim CMO

Bio Green Med Solution, Inc.

Employment of Mark H. Kirschbaum, M.D. as Chief Medical Officer terminated effective January 25, 2024; no severance benefits.
Dr. Brian Schwartz, a board member, appointed interim CMO effective immediately; will not be independent while serving.
Kirschbaum eligible for COBRA health continuation; other benefits end January 31, 2024 if not elected.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark H. Kirschbaum

Chief Medical Officer

BGMS · Bio Green Med Solution, Inc.

Effective: 2024-01-25
Successor: Brian Schwartz
Filed: January 30, 2024, 6:59 PM ET

the employment of Mark H. Kirschbaum, M.D. as Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. (the “Company”) was terminated by the Company, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark H. Kirschbaum departed as Chief Medical Officer at Bio Green Med Solution, Inc..

Action: departure
Role: Chief Medical Officer

Exact text from the filing

the employment of Mark H. Kirschbaum, M.D. as Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. (the “Company”) was terminated by the Company, effective immediately

View on SEC.gov

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-007993

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.